At a glance
- Originator CV Therapeutics
- Class Anti-inflammatories
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 19 Jun 2013 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 12 Nov 1999 Preclinical development for Inflammation in USA (unspecified route)